Review





Similar Products

aggrecan  (Biomatik)
94
Biomatik aggrecan
Effects of CHL on serum biomarkers associated with cartilage degradation and ECM metabolism. SD rats were randomly divided into six groups ( n = 8/group): NC, MIA, MIA + celecoxib (PC, 10 mg/kg/day), and CHL-treated LOW (10 mg/kg/day), MID (30 mg/kg/day), and HIGH (300 mg/kg/day) groups. CHL and celecoxib were administered orally for 6 weeks, with OA induced after 2 weeks of pre-administration by intra-articular injection of MIA. Serum levels of ( A ) COMP, ( B ) CTX-II, ( C ) GAG and ( D ) <t>aggrecan</t> were measured <t>using</t> <t>ELISA</t> kits. Values are presented as the mean ± SD ( n = 8). Statistical significance is indicated by distinct letters, with different letters indicating statistically significant differences between groups. COMP, cartilage oligomeric matrix protein; CTX-II, C-terminal crosslinked telopeptide of type II collagen; and GAG, glycosaminoglycans.
Aggrecan, supplied by Biomatik, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggrecan/Rat+Aggrecan+(AGC)+ELISA+Kit/pmc13610079-83-5-9
Average 94 stars, based on 1 article reviews
aggrecan - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
anti aggrecan antibody  (ABclonal Biotechnology)
97
ABclonal Biotechnology anti aggrecan antibody
Effects of CHL on serum biomarkers associated with cartilage degradation and ECM metabolism. SD rats were randomly divided into six groups ( n = 8/group): NC, MIA, MIA + celecoxib (PC, 10 mg/kg/day), and CHL-treated LOW (10 mg/kg/day), MID (30 mg/kg/day), and HIGH (300 mg/kg/day) groups. CHL and celecoxib were administered orally for 6 weeks, with OA induced after 2 weeks of pre-administration by intra-articular injection of MIA. Serum levels of ( A ) COMP, ( B ) CTX-II, ( C ) GAG and ( D ) <t>aggrecan</t> were measured <t>using</t> <t>ELISA</t> kits. Values are presented as the mean ± SD ( n = 8). Statistical significance is indicated by distinct letters, with different letters indicating statistically significant differences between groups. COMP, cartilage oligomeric matrix protein; CTX-II, C-terminal crosslinked telopeptide of type II collagen; and GAG, glycosaminoglycans.
Anti Aggrecan Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggrecan/ACAN+Rabbit+pAb/pmc13603896-78-4-9
Average 97 stars, based on 1 article reviews
anti aggrecan antibody - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
anti aggrecan  (ABclonal Biotechnology)
97
ABclonal Biotechnology anti aggrecan
Effects of CHL on serum biomarkers associated with cartilage degradation and ECM metabolism. SD rats were randomly divided into six groups ( n = 8/group): NC, MIA, MIA + celecoxib (PC, 10 mg/kg/day), and CHL-treated LOW (10 mg/kg/day), MID (30 mg/kg/day), and HIGH (300 mg/kg/day) groups. CHL and celecoxib were administered orally for 6 weeks, with OA induced after 2 weeks of pre-administration by intra-articular injection of MIA. Serum levels of ( A ) COMP, ( B ) CTX-II, ( C ) GAG and ( D ) <t>aggrecan</t> were measured <t>using</t> <t>ELISA</t> kits. Values are presented as the mean ± SD ( n = 8). Statistical significance is indicated by distinct letters, with different letters indicating statistically significant differences between groups. COMP, cartilage oligomeric matrix protein; CTX-II, C-terminal crosslinked telopeptide of type II collagen; and GAG, glycosaminoglycans.
Anti Aggrecan, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggrecan/ACAN+Rabbit+pAb/pmc13433883-150-2-3
Average 97 stars, based on 1 article reviews
anti aggrecan - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
aggrecan  (ABclonal Biotechnology)
97
ABclonal Biotechnology aggrecan
Effects of CHL on serum biomarkers associated with cartilage degradation and ECM metabolism. SD rats were randomly divided into six groups ( n = 8/group): NC, MIA, MIA + celecoxib (PC, 10 mg/kg/day), and CHL-treated LOW (10 mg/kg/day), MID (30 mg/kg/day), and HIGH (300 mg/kg/day) groups. CHL and celecoxib were administered orally for 6 weeks, with OA induced after 2 weeks of pre-administration by intra-articular injection of MIA. Serum levels of ( A ) COMP, ( B ) CTX-II, ( C ) GAG and ( D ) <t>aggrecan</t> were measured <t>using</t> <t>ELISA</t> kits. Values are presented as the mean ± SD ( n = 8). Statistical significance is indicated by distinct letters, with different letters indicating statistically significant differences between groups. COMP, cartilage oligomeric matrix protein; CTX-II, C-terminal crosslinked telopeptide of type II collagen; and GAG, glycosaminoglycans.
Aggrecan, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggrecan/ACAN+Rabbit+pAb/pm42530800-266-59-60
Average 97 stars, based on 1 article reviews
aggrecan - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
aggrecan rabbit pab  (ABclonal Biotechnology)
97
ABclonal Biotechnology aggrecan rabbit pab
Effects of CHL on serum biomarkers associated with cartilage degradation and ECM metabolism. SD rats were randomly divided into six groups ( n = 8/group): NC, MIA, MIA + celecoxib (PC, 10 mg/kg/day), and CHL-treated LOW (10 mg/kg/day), MID (30 mg/kg/day), and HIGH (300 mg/kg/day) groups. CHL and celecoxib were administered orally for 6 weeks, with OA induced after 2 weeks of pre-administration by intra-articular injection of MIA. Serum levels of ( A ) COMP, ( B ) CTX-II, ( C ) GAG and ( D ) <t>aggrecan</t> were measured <t>using</t> <t>ELISA</t> kits. Values are presented as the mean ± SD ( n = 8). Statistical significance is indicated by distinct letters, with different letters indicating statistically significant differences between groups. COMP, cartilage oligomeric matrix protein; CTX-II, C-terminal crosslinked telopeptide of type II collagen; and GAG, glycosaminoglycans.
Aggrecan Rabbit Pab, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggrecan/ACAN+Rabbit+pAb/pm42476233-221-5-40
Average 97 stars, based on 1 article reviews
aggrecan rabbit pab - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
aggrecan primary antibody  (Proteintech)
96
Proteintech aggrecan primary antibody
Biocompatibility and Bioactivity of PSF and KSF in vivo . (a) Transwell Assay of MSCs after treated with PBS, MAP and PSF. Scale bar = 200 μm. (b) Wound Healing Assay of MSCs at 0h and 24h. Scale bar = 200 μm. <t>(c)</t> <t>Immunofluorescent</t> staining of cell pellets after 21 days of co-culture. Blue: DAPI; Green: ActinGreen; Red: <t>Aggrecan.</t> Scale bar = 200 μm. (d) Alcian blue staining of 2D cultured MSCs after 14 days. Scale bar = 200 μm. (e) Cell viability of MSCs at day 3 after co-culture. (f) The cell number of MSCs migrated from upper to lower chamber in Transwell assay. (g) The average distance MSCs migrated from injured margin in wound healing assay. (h–j) qRT-PCR of Col2a1 , Acan and Sox9 mRNA relative expression ratio compared with PBS group. ns: p > 0.05; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001.
Aggrecan Primary Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggrecan/Aggrecan+Antibody/pmc12859459-243-5-9
Average 96 stars, based on 1 article reviews
aggrecan primary antibody - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
antibodies against aggrecan  (Servicebio Inc)
86
Servicebio Inc antibodies against aggrecan
Biocompatibility and Bioactivity of PSF and KSF in vivo . (a) Transwell Assay of MSCs after treated with PBS, MAP and PSF. Scale bar = 200 μm. (b) Wound Healing Assay of MSCs at 0h and 24h. Scale bar = 200 μm. <t>(c)</t> <t>Immunofluorescent</t> staining of cell pellets after 21 days of co-culture. Blue: DAPI; Green: ActinGreen; Red: <t>Aggrecan.</t> Scale bar = 200 μm. (d) Alcian blue staining of 2D cultured MSCs after 14 days. Scale bar = 200 μm. (e) Cell viability of MSCs at day 3 after co-culture. (f) The cell number of MSCs migrated from upper to lower chamber in Transwell assay. (g) The average distance MSCs migrated from injured margin in wound healing assay. (h–j) qRT-PCR of Col2a1 , Acan and Sox9 mRNA relative expression ratio compared with PBS group. ns: p > 0.05; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001.
Antibodies Against Aggrecan, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aggrecan/aggrecan+anti/pm42275868-129-22-26
Average 86 stars, based on 1 article reviews
antibodies against aggrecan - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Effects of CHL on serum biomarkers associated with cartilage degradation and ECM metabolism. SD rats were randomly divided into six groups ( n = 8/group): NC, MIA, MIA + celecoxib (PC, 10 mg/kg/day), and CHL-treated LOW (10 mg/kg/day), MID (30 mg/kg/day), and HIGH (300 mg/kg/day) groups. CHL and celecoxib were administered orally for 6 weeks, with OA induced after 2 weeks of pre-administration by intra-articular injection of MIA. Serum levels of ( A ) COMP, ( B ) CTX-II, ( C ) GAG and ( D ) aggrecan were measured using ELISA kits. Values are presented as the mean ± SD ( n = 8). Statistical significance is indicated by distinct letters, with different letters indicating statistically significant differences between groups. COMP, cartilage oligomeric matrix protein; CTX-II, C-terminal crosslinked telopeptide of type II collagen; and GAG, glycosaminoglycans.

Journal: Nutrients

Article Title: CHL Attenuates MIA-Induced Osteoarthritis by Regulating Inflammatory, Catabolic, and Anabolic Pathways Associated with Cartilage and Subchondral Bone Degeneration

doi: 10.3390/nu18183031

Figure Lengend Snippet: Effects of CHL on serum biomarkers associated with cartilage degradation and ECM metabolism. SD rats were randomly divided into six groups ( n = 8/group): NC, MIA, MIA + celecoxib (PC, 10 mg/kg/day), and CHL-treated LOW (10 mg/kg/day), MID (30 mg/kg/day), and HIGH (300 mg/kg/day) groups. CHL and celecoxib were administered orally for 6 weeks, with OA induced after 2 weeks of pre-administration by intra-articular injection of MIA. Serum levels of ( A ) COMP, ( B ) CTX-II, ( C ) GAG and ( D ) aggrecan were measured using ELISA kits. Values are presented as the mean ± SD ( n = 8). Statistical significance is indicated by distinct letters, with different letters indicating statistically significant differences between groups. COMP, cartilage oligomeric matrix protein; CTX-II, C-terminal crosslinked telopeptide of type II collagen; and GAG, glycosaminoglycans.

Article Snippet: ELISA kits for GAGs and aggrecan were obtained from Biomatik (Kitchener, ON, Canada).

Techniques: Injection, Enzyme-linked Immunosorbent Assay

Biocompatibility and Bioactivity of PSF and KSF in vivo . (a) Transwell Assay of MSCs after treated with PBS, MAP and PSF. Scale bar = 200 μm. (b) Wound Healing Assay of MSCs at 0h and 24h. Scale bar = 200 μm. (c) Immunofluorescent staining of cell pellets after 21 days of co-culture. Blue: DAPI; Green: ActinGreen; Red: Aggrecan. Scale bar = 200 μm. (d) Alcian blue staining of 2D cultured MSCs after 14 days. Scale bar = 200 μm. (e) Cell viability of MSCs at day 3 after co-culture. (f) The cell number of MSCs migrated from upper to lower chamber in Transwell assay. (g) The average distance MSCs migrated from injured margin in wound healing assay. (h–j) qRT-PCR of Col2a1 , Acan and Sox9 mRNA relative expression ratio compared with PBS group. ns: p > 0.05; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001.

Journal: Bioactive Materials

Article Title: Precisely regulated physically-crosslinked carriers enable synergetic release of bioactive factors for MSC-mediated cartilage regeneration

doi: 10.1016/j.bioactmat.2026.01.009

Figure Lengend Snippet: Biocompatibility and Bioactivity of PSF and KSF in vivo . (a) Transwell Assay of MSCs after treated with PBS, MAP and PSF. Scale bar = 200 μm. (b) Wound Healing Assay of MSCs at 0h and 24h. Scale bar = 200 μm. (c) Immunofluorescent staining of cell pellets after 21 days of co-culture. Blue: DAPI; Green: ActinGreen; Red: Aggrecan. Scale bar = 200 μm. (d) Alcian blue staining of 2D cultured MSCs after 14 days. Scale bar = 200 μm. (e) Cell viability of MSCs at day 3 after co-culture. (f) The cell number of MSCs migrated from upper to lower chamber in Transwell assay. (g) The average distance MSCs migrated from injured margin in wound healing assay. (h–j) qRT-PCR of Col2a1 , Acan and Sox9 mRNA relative expression ratio compared with PBS group. ns: p > 0.05; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001.

Article Snippet: Immunofluorescent staining was performed with Aggrecan primary antibody (13880-1-AP, Proteintech, USA), ActinGreen ( R37110 , Thermo, USA) and DAPI (Solarbio, China) and observed with 3D reconstruction under high content imaging system (PerkinElmer, Operetta CLS, USA).

Techniques: In Vivo, Transwell Assay, Wound Healing Assay, Staining, Co-Culture Assay, Cell Culture, Quantitative RT-PCR, Expressing